CDL March Issue The Liver in Systemic Disease: Rheumatic and connective tissue disorders

Wednesday, March 30, 2016

CDL March Issue The Liver in Systemic Disease: Rheumatic and connective tissue disorders

Clinical Liver Disease is an official digital educational learning resource from the American Association for the Study of Liver Diseases. Visitors are able to view videos, access full text articles, and download files in either HTML or PDF formats.

Clinical Liver Disease© The American Association for the Study of Liver Diseases

Volume 7, Issue 3 Pages 45 - 67, March 2016

Special Issue: Emerging Liver Scholars, Consultations in Hepatology, Ethics in Clinical Liver Disease, Integrated Health and The Liver in Systemic Disease
The latest issue of Clinical Liver Disease is available on Wiley Online Library

Emerging Liver Scholars
The Liver in Systemic Disease
Guest Edited by John O'Grady, MD
Rheumatic and connective tissue disorders (pages 64–67)
Deepak Joshi
Article first published online: 29 MAR 2016 | DOI: 10.1002/cld.536
Watch a video presentation of this article

Guest Edited by William Sanchez, MD
Noninvasive evaluation of nonalcoholic fatty liver disease (pages 45–47)
Benjamin Renelus and Temitope Foster
Article first published online: 29 MAR 2016 | DOI: 10.1002/cld.538
Watch a video presentation of this article

Consultations in Hepatology
Guest Edited by Mary Rinella, MD
Elevated creatinine in a patient with cirrhosis (pages 48–52)
Heather L. Klavan and Brett E. Fortune
Article first published online: 29 MAR 2016 | DOI: 10.1002/cld.534
Watch a video presentation of this article
Watch the interview with the author

Unexplained ascites (pages 53–56)
Ruben Hernaez and James P. Hamilton
Article first published online: 29 MAR 2016 | DOI: 10.1002/cld.537
Watch a video presentation of this article
Watch the interview with the author

Ethics in Clinical Liver Disease
Guest Edited by Andrew Aronsohn, MD
Ethical review of the responsibilities of the patient advocate in living donor liver transplant (pages 57–59)
Rebecca Hays and Arthur J. Matas
Article first published online: 29 MAR 2016 | DOI: 10.1002/cld.533
Watch a video presentation of this article
Watch the interview with the author

Integrated Health
Guest Editor by Felix Stickel, MD
Drug-induced liver injury in the United States: A review of multi-ingredient supplements (pages 60–63)
Elizabeth Zheng and Victor Navarro
Article first published online: 29 MAR 2016 | DOI: 10.1002/cld.535
Watch a video presentation of this article
Watch the interview with the author

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Contact hcvnewdrugs@gmail.com

Helpful Links
HCV Education
Research Articles
Fibrosis
Cirrhosis
Liver Cancer
Liver Transplants
Fatty Liver Disease
HCV-elderly
Possible Side Effects Of HCV Therapy
Other Conditions Related To HCV
HCV Genotypes/treatment
HCV Newsletters
Premier Hepatitis C Websites

The above links offer data about interferon-free regimens approved to treat HCV, with learning activities, editorials, and tips from patient bloggers who understand the ups and downs of liver disease, in addition to a list of outstanding hepatitis C websites, blogs and support forums.

On Twitter
I highly suggest you follow Henry E. Chang on Twitter if you are interested in reading articles about the treatment and management of hepatitis C.

The controversy over expensive new drugs for hepatitis C
Link to research and news articles addressing the high cost of hepatitis C drugs; insurance restrictions - private insurers/Medicaid - and availability of generic versions/India, Egypt and other lower-income countries or through online "buyers clubs"

Latest Update Feb 12, 2019

Lancet Study:

Direct-acting antivirals reduce risk of premature mortality and liver cancer for people with chronic hepatitis C

These findings firmly counter those of a Cochrane review of direct-acting antiviral treatment trials that could neither confirm nor reject if direct-acting antivirals had an effect on long-term HCV-related morbidity and mortality. They also provide the best evidence to date to support guidance documents that recommend direct-acting antiviral treatment for all patients with chronic HCV infection.

The Controversy
Rebuttal over Cochrane Review of DAAs
A systematic review published by the Cochrane Collaboration suggested achieving SVR (cure) for patients using hepatitis C direct-acting antivirals (DAAs) doesn't correlate with any long term benefits. View each rebuttal and all ongoing media coverage.